Anna Kaltenboeck

767 total citations
34 papers, 596 citations indexed

About

Anna Kaltenboeck is a scholar working on Economics and Econometrics, Pharmacology and Neurology. According to data from OpenAlex, Anna Kaltenboeck has authored 34 papers receiving a total of 596 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Economics and Econometrics, 7 papers in Pharmacology and 5 papers in Neurology. Recurrent topics in Anna Kaltenboeck's work include Health Systems, Economic Evaluations, Quality of Life (15 papers), Pharmaceutical Economics and Policy (11 papers) and Pharmaceutical industry and healthcare (6 papers). Anna Kaltenboeck is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (15 papers), Pharmaceutical Economics and Policy (11 papers) and Pharmaceutical industry and healthcare (6 papers). Anna Kaltenboeck collaborates with scholars based in United States, South Korea and Taiwan. Anna Kaltenboeck's co-authors include Howard G. Birnbaum, Leigh Ann White, David Mallett, Peter B. Bach, R.L. Robinson, Jackson Tang, Scott J. Johnson, Andrew Siderowf, Matthew Davis and Andrew P. Yu and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Gastroenterology.

In The Last Decade

Anna Kaltenboeck

32 papers receiving 577 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anna Kaltenboeck United States 13 201 191 181 125 86 34 596
Carolin Miltenburger Sweden 16 206 1.0× 166 0.9× 41 0.2× 129 1.0× 43 0.5× 28 759
Alejandra Cano Spain 10 123 0.6× 57 0.3× 346 1.9× 46 0.4× 35 0.4× 20 602
Katy Gallop United Kingdom 16 214 1.1× 37 0.2× 58 0.3× 47 0.4× 45 0.5× 42 774
Elena Telaro Italy 8 117 0.6× 50 0.3× 26 0.1× 143 1.1× 71 0.8× 11 572
E Grace Canada 12 137 0.7× 81 0.4× 122 0.7× 36 0.3× 34 0.4× 27 792
Yohanne Kidolezi United States 7 144 0.7× 53 0.3× 84 0.5× 20 0.2× 68 0.8× 10 480
Ashley F. Slagle United States 8 78 0.4× 113 0.6× 26 0.1× 30 0.2× 64 0.7× 26 437
L. Humphrey United Kingdom 11 235 1.2× 45 0.2× 193 1.1× 10 0.1× 67 0.8× 28 664
Tyler G. Kinzy United States 15 60 0.3× 89 0.5× 21 0.1× 60 0.5× 101 1.2× 33 633
R Sambrook United Kingdom 10 180 0.9× 60 0.3× 20 0.1× 25 0.2× 85 1.0× 18 583

Countries citing papers authored by Anna Kaltenboeck

Since Specialization
Citations

This map shows the geographic impact of Anna Kaltenboeck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Kaltenboeck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Kaltenboeck more than expected).

Fields of papers citing papers by Anna Kaltenboeck

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Kaltenboeck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Kaltenboeck. The network helps show where Anna Kaltenboeck may publish in the future.

Co-authorship network of co-authors of Anna Kaltenboeck

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Kaltenboeck. A scholar is included among the top collaborators of Anna Kaltenboeck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Kaltenboeck. Anna Kaltenboeck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mattingly, T. Joseph, et al.. (2024). Implementing Maximum Fair Price Without Hurting Pharmacies. JAMA Health Forum. 5(5). e240921–e240921. 1 indexed citations
2.
Hernandez, Inmaculada, et al.. (2023). Reimbursement to Pharmacies for Generic Drugs by Medicare Part D Sponsors. JAMA. 330(24). 2390–2390. 3 indexed citations
3.
Korenstein, Deborah, et al.. (2021). Priceless Knowledge: Attitudes and Awareness Around Drug Pricing Among US Medical Students. Medical Science Educator. 31(2). 489–494.
4.
Kaltenboeck, Anna. (2020). Pharmaceutical Products and Their Value: Lessons Learned and the Path Ahead. Value in Health. 23(4). 421–424. 5 indexed citations
5.
Kaltenboeck, Anna & S. Vincent Rajkumar. (2020). The Case for Masks. Mayo Clinic Proceedings. 95(6). 1132–1134. 1 indexed citations
6.
Kaltenboeck, Anna, et al.. (2020). Grounding Value‐Based Drug Pricing in Population Health. Clinical Pharmacology & Therapeutics. 107(6). 1290–1292. 4 indexed citations
7.
Morgan, Steven G., Chester B. Good, Christine Leopold, et al.. (2018). An analysis of expenditures on primary care prescription drugs in the United States versus ten comparable countries. Health Policy. 122(9). 1012–1017. 6 indexed citations
8.
Carter, Gebra Cuyún, Anna Kaltenboeck, Jasmina I. Ivanova, et al.. (2016). Treatment patterns in patients with advanced gastric cancer in Taiwan. Asia-Pacific Journal of Clinical Oncology. 13(3). 185–194. 11 indexed citations
9.
Rajan, Neil, Anna Kaltenboeck, Jasmina Ivanova, et al.. (2014). HEALTH CARE RESOURCE USE AMONG ADVANCED GASTRIC CANCER PATIENTS IN TAIWAN AND SOUTH KOREA. Value in Health. 17(7). A734–A734. 1 indexed citations
10.
Carter, Gebra Cuyún, Anna Kaltenboeck, Jasmina Ivanova, et al.. (2014). Real-world treatment patterns among patients with advanced gastric cancer in South Korea.. Journal of Clinical Oncology. 32(3_suppl). 152–152. 1 indexed citations
11.
Kaltenboeck, Anna, et al.. (2013). Health Care Resource Use And Costs In Patients With Type 2 Diabetes Mellitus After Treatment Initiation With Saxagliptin Or Sitagliptin. Value in Health. 16(3). A161–A161. 1 indexed citations
12.
Johnson, Scott J., Anna Kaltenboeck, Howard G. Birnbaum, et al.. (2013). Costs of Parkinson’s Disease in a Privately Insured Population. PharmacoEconomics. 31(9). 799–806. 24 indexed citations
13.
Kaltenboeck, Anna, Genia Long, Eleanor Hayes‐Larson, & Gilberto Lopes. (2013). Assessing the impact of substandard copy medicines in developing countries: the experience with imatinib copies. Expert Review of Clinical Pharmacology. 6(6). 691–701. 5 indexed citations
14.
Kaltenboeck, Anna, Shonda A. Foster, Jasmina Ivanova, et al.. (2012). The Direct and Indirect Costs among U.S. Privately Insured Employees with Hypogonadism. The Journal of Sexual Medicine. 9(9). 2438–2447. 20 indexed citations
15.
Yu, Andrew P., Rym Ben-Hamadi, Eric Q. Wu, et al.. (2011). Impact of initiation timing of SSRI or SNRI on depressed adolescent healthcare utilization and costs. Journal of Medical Economics. 14(4). 508–515. 6 indexed citations
16.
Rutgeerts, Paul, Walter Reinisch, Roopal Thakkar, et al.. (2010). 644 Early Mucosal Healing Status Predicts Long-Term Clinical Benefits for Adalimumab-Treated Patients With Moderate to Severe Crohn's Disease. Gastroenterology. 138(5). S–85. 10 indexed citations
17.
White, Leigh Ann, R.L. Robinson, Andrew P. Yu, et al.. (2009). Comparison of Health Care Use and Costs in Newly Diagnosed and Established Patients With Fibromyalgia. Journal of Pain. 10(9). 976–983. 40 indexed citations
18.
Wu, Eric Q., Steven R. Feldman, Anna Kaltenboeck, et al.. (2008). Utilization pattern of etanercept and its cost implications in moderate to severe psoriasis in a managed care population. Current Medical Research and Opinion. 24(12). 3493–3501. 12 indexed citations
19.
White, Leigh Ann, et al.. (2008). (163) Medical care and APS guideline-related prescription drug use in newly diagnosed and established fibromyalgia patients. Journal of Pain. 9(4). 16–16. 8 indexed citations
20.
White, Leigh Ann, Howard G. Birnbaum, Anna Kaltenboeck, et al.. (2008). Employees With Fibromyalgia: Medical Comorbidity, Healthcare Costs, and Work Loss. Journal of Occupational and Environmental Medicine. 50(1). 13–24. 148 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Carolin Miltenburger Breakdown of academic impact, for papers by Alejandra Cano Breakdown of academic impact, for papers by Katy Gallop Breakdown of academic impact, for papers by Elena Telaro Breakdown of academic impact, for papers by E Grace Breakdown of academic impact, for papers by Yohanne Kidolezi Breakdown of academic impact, for papers by Ashley F. Slagle Breakdown of academic impact, for papers by L. Humphrey Breakdown of academic impact, for papers by Tyler G. Kinzy Breakdown of academic impact, for papers by R Sambrook
Rankless by CCL
2026